Detalhe da pesquisa
1.
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Pharm Res
; 40(7): 1657-1672, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-36418671
2.
The role of immunophilins in viral infection.
Biochim Biophys Acta
; 1850(10): 2103-10, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25445708
3.
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.
Antimicrob Agents Chemother
; 60(1): 693-8, 2016 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26552985
4.
Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.
Antimicrob Agents Chemother
; 59(5): 2496-507, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25666154
5.
The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Antimicrob Agents Chemother
; 58(6): 3327-34, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24687498
6.
Correlation between NS5A dimerization and hepatitis C virus replication.
J Biol Chem
; 287(36): 30861-73, 2012 Aug 31.
Artigo
Inglês
| MEDLINE | ID: mdl-22801423
7.
HCV NS5A and IRF9 compete for CypA binding.
J Hepatol
; 58(1): 16-23, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22902549
8.
Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice.
Sci Rep
; 13(1): 4594, 2023 03 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36944714
9.
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
Antimicrob Agents Chemother
; 56(7): 3888-97, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22585215
10.
Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.
Antimicrob Agents Chemother
; 56(6): 3336-43, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22430971
11.
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
Antimicrob Agents Chemother
; 56(10): 5113-21, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22802259
12.
Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Pharm Res
; 29(11): 3156-68, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22736232
13.
Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study.
Commun Med (Lond)
; 2: 129, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36238348
14.
Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
Sci Rep
; 12(1): 8224, 2022 05 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35581262
15.
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.
Proc Natl Acad Sci U S A
; 105(8): 3088-93, 2008 Feb 26.
Artigo
Inglês
| MEDLINE | ID: mdl-18287023
16.
Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.
Proc Natl Acad Sci U S A
; 105(14): 5525-30, 2008 Apr 08.
Artigo
Inglês
| MEDLINE | ID: mdl-18378908
17.
The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
PLoS One
; 16(5): e0251934, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34014993
18.
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
Antiviral Res
; 191: 105089, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34010661
19.
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
Viruses
; 13(8)2021 08 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34452519
20.
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
Antiviral Res
; 192: 105122, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34186107